К. Yu. Nikolaev

Часть публикаций из профиля, по году от новых к старым. Это не полный список последних работ автора; работы без года — в конце.

• Machine Learning Models Integrating CYP2C19 Genotypes for Long-Term Risk Prediction and Personalized Antiplatelet Therapy Selection in Myocardial Infarction2026
• Clinical and diagnostic significance of heart fatty acid-binding protein (H-FABP) in cardiological practice2026
• Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES2025
• Evaluation of the efficacy of combined pharmacoprotection with ticagrelor and high-dose statins in patients with myocardial infarction and different genotypes of rs2305948 VEGFR22025
• Analysis of associations of rs2305948 genotypes of KDR (VEGFR2) gene, collateral coronary blood flow degree and statin treatment dose intensity with long-term prognosis in patients with myocardial infarction2025
• Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes2023 · аннотациясвернуть

  BACKGROUND: In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces cardiovascular and kidney failure outcomes. Finerenone also…

• Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial2022
• Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis2022 · аннотациясвернуть

  OBJECTIVE: Finerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD and FIGARO-DKD phase 3 studies. Effects of finerenone on…